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Rearranged during transfection (RET) fusions have been newly iden-
tified in approximately 1% of patients with primary lung tumors. 
However, patient-derived lung cancer cell lines harboring RET 
fusions have not yet been established or identified, and therefore, the 
effectiveness of an RET inhibitor on lung tumors with endogenous 
RET fusion has not yet been studied. In this study, we report identi-
fication of CCDC6-RET fusion in the human lung adenocarcinoma 
cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET 
inhibitor, vandetanib, among 39 non–small lung cancer cell lines. 
The xenograft tumor of LC-2/ad showed cribriform acinar structures, 
a morphologic feature of primary RET fusion–positive lung adeno-
carcinomas. LC-2/ad cells could provide useful resources to analyze 
molecular functions of RET-fusion protein and its response to RET 
inhibitors.
Key Words: RET fusion, Lung adenocarcinoma, Cell line, 
Vandetanib.
(J Thorac Oncol. 2012;7: 1872–1876)
Lung cancer is the leading cause of cancer mortality in developed countries. Molecularly targeted therapy is a 
new therapeutic modality now under intense investigation.1 
KRAS mutations, epidermal growth factor receptor (EGFR) 
mutations, and anaplastic lymphoma receptor tyrosine kinase 
(ALK) fusions are well-known driver mutations identified in 
individuals with lung adenocarcinoma. Molecular analyses 
have demonstrated that EGFR-mutated non–small-cell lung 
tumors are usually sensitive to the EGFR inhibitors gefitinib 
and erlotinib, and ALK fusion non–small-cell lung tumors are 
sensitive to the ALK inhibitor crizotinib. Lung tumors with 
ROS1 fusions also respond to crizotinib.2
Recently, several independent studies newly identified 
RET fusions (KIF5B-RET or CCDC6-RET) in approximately 
1% of patients with primary lung tumors.3–9 RET fusions were 
mutually exclusive of EGFR, KRAS, and ALK mutations. 
Although these studies suggested that RET kinase inhibitors 
would be effective for a subgroup of lung tumors harboring 
RET fusions, the clinical benefits of RET kinase inhibitors 
in these patients have not been clarified yet. Studies using 
patient-derived lung cancer cell lines harboring RET fusions 
are now needed to decide the best optimal drug treatments; 
however, lung cancer cell lines with endogenous RET fusions 
have not been established nor identified to date.10
In this study, we found that a lung adenocarcinoma cell 
line, LC-2/ad, harbored CCDC6-RET fusion, and examined 
its sensitivity to vandetanib, a multikinase inhibitor of RET, 
vascular endothelial growth factor receptor-2, and EGFR. To 
the best of our knowledge, this is the first report to identify 
a patient-derived lung cancer cell line harboring RET fusion 
and demonstrate its sensitivity to a RET kinase inhibitor. The 
availability of this cell line would facilitate studies on optimal 
drug treatments and the biological properties of RET fusion–
positive lung adenocarcinomas.
MATERIALS AND METHODS
Cell Lines and Medium
We used 39 non–small-cell lung cancer cell lines, 34 
adenocarcinoma cell lines (H23, H292, H358, H441, H522, 
H596, H650, H1395, H1648, H1650, H1651, H1703, 
H1781, H1793, H1838, H1975, H1993, H2009, H2087, 
H2228, H2405, HCC827, HCC4006, Calu-3, A549, ABC1, 
PC3, VMRC-LCD, RELF-LC-Ad1, RELF-LC-Ad2, HLC-
1, LC-2/ad, RERF-LC-KJ, and L27), four large-cell carci-
noma cell lines (Lu65, H460, H661, and H1299), and one 
adenosquamous cell line (H596). Detailed information on 
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the 39 cell lines is available in our previous reports.11,12 
Among the 39 cell lines, EGFR mutations were detected 
in five cell lines: HCC827, HCC4006, PC3, H1650, 
and H1975. EGFR mutation status of the five cell lines 
(Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A337). We have not checked the 
39 cell lines for ALK fusion in our hands, but H2228 has 
been reported to harbor ALK fusion13 (Supplementary Table 
1, Supplemental Digital Content 1, http://links.lww.com/
JTO/A337).
RET Fusion–Specific Polymerase Chain Reaction
We used fusion-specific reverse-transcriptase polymerase 
chain reaction (RT-PCR) with the forward primer, CCDC6-197F 
(5′-TGCAGCAAGAGAACAAGGTG-3′), the forward primer, 
KIF5B-867F (5′-ATCCAGTTCGTCCTGTTCAGAGC-3′), 
KIF5B-2265R (5′-AGCCACAGATCAGGAAAAGA-3′), and 
reverse primer, RET-2381R (5′-CAGGCCCCATACAATTTGAT- 
3′), following the method by Takeuchi et al.4
Genetic and Protein Analysis of Cell Lines
The DNA, RNA, and cell lysates were prepared from 
cell lines by standard procedures. Experimental details of 
sequencing, copy number analyses, and Western blotting are 
given in our previous reports 11,12 (antibodies for Western blot-
ting are listed in Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A337).
Cell-Proliferation Assay
Cell viability was measured by the Cell Counting Kit-8 
assay (Dojindo, Kumamoto, Japan) following the manufac-
turer’s instructions.11
Xenograft Tumor of LC-2/ad
We established a xenograft tumor of LC-2/ad by inject-
ing cell suspensions (5 × 106) into the flank of a 6-week-old 
female severe combined immunodeficient mouse NOD C.B-
17-Prkdc scid/J (NOD/SCID).
Immunohistochemistry
A formalin-fixed, paraffin-embedded xenograft tumor 
specimen of LC-2/ad was analyzed by immunohistochem-
istry using antibodies to RET, TTF-1, Napsin A, and thyro-
globulin (sources of antibodies are given in Supplementary 
Table 2, Supplemental Digital Content 5, http://links.lww.
com/JTO/A341).
FIGURE 1.  Dose-response curves of three 
cell lines, LC-2/ad, HCC827, and H1993. 
HCC827 harbors EGFR Exon 19 deletion 
(746–750) and H1993 expresses wild-type 
EGFR. The x axis indicates the log10 (concen-
tration of vandetanib [A] and gefitinib [B]), 
and the y axis indicates the % of cell viability 
= (mean absorbance in test wells)/(mean 
absorbance in control well) × 100. A, LC-2/
ad and HCC827 were sensitive to vandetanib 
(IC50 values were 2.9E-08 and 6.9E-09, 
respectively), but H1993 was resistant to 
vandetanib (IC50 value was 5.1E-04). B, 
HCC827 was sensitive to gefitinib (inhibi-
tory concentration 50 value was 1.8E-10), 
but LC-2/ad and H1993 were resistant to 
gefitinib (inhibitory concentration 50 values 
were 1.8E-05 and 4.0E-06, respectively). 
EGFR, epidermal growth factor receptor.
FIGURE 2.  Effects of vandetanib and gefitinib on the phos-
phorylation levels of EGFR, ERK, and AKT in LC-2/ad, HCC827, 
and H1993. Gefitinib efficiently led to dephosphorylation of 
EGFR, ERK, and AKT in HCC827, but not in LC-2/ad and H1993. 
Vandetanib efficiently led to dephosphorylation of ERK and AKT 
in LC-2/ad and HCC827, but not in H1993.EGFR, EGFR, epider-
mal growth factor receptor; ERK, extracellular signal-regulated 
kinase; AKT, v-akt murine thymoma viral oncogene homolog 1.
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RESULTS AND DISCUSSION
Sensitivity of Non–Small-Cell Carcinoma 
Cell Lines to Vandetanib and Gefitinib
We examined and compared the efficacy of vande-
tanib (ZD6474) and gefitinib (both provided by AstraZeneca, 
London, England) in 39 non–small lung carcinoma cell lines 
(Supplementary Figure 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A338). Most cell lines showed simi-
lar sensitivities to the two kinase inhibitors; however, a notable 
exception was the lung adenocarcinoma, LC-2/ad, which was 
resistant to gefitinib, but highly sensitive to vandetanib. To 
illustrate this distinctive feature of LC-2/ad, the dose-response 
curves of LC-2/ad for gefitinib and vandetanib are shown in 
Figure 1, together with those of HCC827 (an EGFR-mutated 
cell line) and H1993 (an MET-amplified cell line).
Effects of Vandetanib on the Phosphorylation 
of Downstream Effectors of Growth Factor 
Receptors, ERK and AKT of LC-2/ad
We tested the effects of vandetanib and gefitinib treat-
ments on ERK and AKT signaling in LC-2/ad, HCC827, and 
H1993. Results are shown in Figure 2. Vandetanib (1 × 10−6 
M) effectively abolished baseline phosphorylation of ERK 
and AKT in both LC-2/ad and HCC827, but not in H1993. In 
FIGURE 3.  Identification of CCDC6-RET fusion in LC-2/ad by fusion-specific RT-PCR. A, Bar graphs of gene-level expressions of 
RET in the 39 cell lines. B, Results for fusion-specific RT-PCR of LC-2/ad: with the forward primer CCDC6-197F and reverse primer 
RET-2381R (Lane 1), with the forward primer KIF5B-867F and reverse primer RET-2381R (Lane 2), and with the forward primer 
KIF5B-2265F and reverse primer RET-2381R (Lane 3). A PCR product of an expected size (352 base pair) was amplified in Lane 
1, but not in Lane 2 or Lane 3. Molecular weight marker: φX174-HAE digest. C, RET-CCDC6 fusion was captured only in LC-2/
ad and was not captured in any of the other cell lines tested. The results for eight cell lines are shown: Lane 1, A549; Lane 2, 
ABC1; Lane 3, Calu-3; Lane 4, PC3; Lane 5, RERF-LC-KJ; Lane 6, HLC-1; Lane 7, L27; Lane 8, LC-2/ad; and Lane 9, VMRC-LCD). 
Molecular weight marker: φX174-HAE digest. D, Direct sequencing of the PCR product containing RET-CCDC6 fusion. PCR, poly-
merase chain reaction; RT-PCR, reverse-transcriptase polymerase chain reaction.
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contrast, gefitinib effectively abolished baseline phosphoryla-
tion of ERK and AKT only in HCC827. This suggests that, in 
LC-2/ad, ERK and AKT are activated through a vandetanib-
sensitive pathway other than EGFR signaling.
Identification of RET Fusion in LC-2/ad.
Among the tyrosine kinases targeted by vandetanib, 
RET was an obvious candidate molecule. First, in our oligo-
nucleotide array analysis data of 39 cell lines, LC/2-ad showed 
lower expressions of vascular endothelial growth factor recep-
tor-2 and EGFR, but distinctively higher expression of RET 
than that of other cell lines (Fig. 3A and Supplementary Data 
1, Supplemental Digital Content 3, http://links.lww.com/JTO/
A339). Second, the result of an independently performed exon 
array analysis of LC-2/ad suggested the existence of RET 
fusion in LC-2/ad (not shown).
To directly demonstrate RET fusion in LC-2/ad, we per-
formed fusion-specific RT-PCR with primers sets that detect 
RET-CCDC6 or RET-KIF5B (see Materials and Methods).4 
RET-CCDC6 fusion, but not RET-KIF5B fusion, was detected 
in LC-2/ad. No PCR product was amplified in any of the other 
cell lines examined (Fig. 3B and C). Direct sequence analysis 
of RT-PCR products demonstrated a fusion between CCDC6 
exon1 and RET exon12 (Fig. 3D). An independently per-
formed 5′ rapid amplification of complementary DNA ends 
(5′-RACE) using a primer complementary to RET demon-
strated the same fusion in LC-2/ad (data not shown). Although 
CCDC6-RET fusions have now been found in many lung can-
cers, these cases have the same breakpoints; exon 1 of CCDC6 
is fused to exon 12 of RET at the cDNA level. The thyroid 
cancer cell line TPC-1 also harbors CCDC6-RET fusion at the 
same site.14 However, we have not checked the breakpoints 
of the RET and CCDC6 genes in LC-2/ad at the genomic 
level. Thus, it would be of interest to further determine and 
characterize the genomic breakpoints in CCDC6-RET fusion– 
positive tumors.
Histopathologic Characteristics of an 
Established Xenograft Tumor of LC-2/ad
LC-2/ad was established from the pleural effusion of 
a 51-year-old female pulmonary adenocarcinoma patient 
whose smoking status was unknown; the tumor histology was 
reported to be a moderately differentiated adenocarcinoma 
with distinct glandular structures.15 To confirm this earlier 
finding and to further examine the histopathologic features 
of this cell line, we established a xenograft tumor of LC-2/ad 
FIGURE 4.  Histopathologic characteristics of an established xenograft tumor of LC-2/ad. A, The main histopathologic diagno-
sis of the tumor was acinar-predominant adenocarcinoma showing a cribriform pattern (hematoxylin and eosin staining, ×200). 
B, The tumor was positive for RET (RET immunostaining, ×200). C, The tumor was positive for Napsin A (Napsin A immunostain-
ing, ×200). D, The tumor was negative for thyroglobulin (Thyroglobulin immunostaining, ×200).
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in an NOD/SCID mouse. The results are shown in Figure 4A 
and Supplementary Figure 2A (Supplemental Digital Content 
4, http://links.lww.com/JTO/A340). The main histopathol-
ogy of the tumor was acinar-predominant adenocarcinoma 
showing a cribriform pattern with mucin production. This 
finding supports the proposal by Takeuchi et al.4 that a cribri-
form acinar pattern is a distinctive histopathologic feature of 
kinase-fusion tumors. In the periphery of the tumor, a micro-
papillary component was also seen (Supplementary Figure 
2B, Supplemental Digital Content 4, http://links.lww.com/
JTO/A340). Immunohistochemically, the tumor was positive 
for RET, Napsin A, and TTF-1, but negative for thyroglobulin 
(Fig. 4C and 4D and Supplementary Figure 2C, Supplemental 
Digital Content 4, http://links.lww.com/JTO/A340), which 
confirmed that LC-2/ad originated from the primary lung ade-
nocarcinoma and not from a thyroid tumor.
As far as we know, this is the first report to demonstrate 
that a patient-derived lung adenocarcinoma cell line harbor-
ing endogenous RET fusions is sensitive to vandetanib. This 
cell line may be a useful tool to address the following issues 
regarding RET-fusion genes. First, this cell line can be used 
for drug screening. We have not examined the sensitivities 
to the RET inhibitors other than vandetanib, but it will be 
interesting to test the sensitivity of LC-2/ad to sorafenib and 
sunitinib as well. The LC-2/ad xenografts can be also used 
for examination of the sensitivity in vivo. Second, this cell 
line may be used to study the intracellular signaling pathway 
of RET fusion in lung tumors. Third, vandetanib-resistant cell 
line may be generated from LC-2/ad and such a resistant sub-
line would be invaluable in the study of the mechanisms of 
acquired resistance to vandetanib. Fourth, although the acinar-
predominant pattern has been proposed as a morphologic fea-
ture of tumors harboring kinase fusions,4 why kinase-fusion 
genes lead to such characteristic morphology is currently 
unclear. Thus, this cell line may provide a useful resource to 
study the molecular basis for the molecular–morphologic cor-
relations in cancer.
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